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Background: Serum magnesium (Mg) levels may be impacted by inpatient diuresis and sympathetic drive. The clinical profile and prognostic 
significance of serum Mg concentration in patients (pts) hospitalized for heart failure with reduced ejection fraction (HHFrEF) is unclear.
methods: In this analysis of the placebo group of EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan), we 
evaluated the clinical characteristics and outcomes [all-cause mortality (ACM) and cardiovascular mortality or hospitalization for HF (CVM+HHF)] of 
1,982 HHFrEF pts stratified by baseline Mg levels.
results: The mean baseline Mg level was 2.1±0.3 mg/dL (interquartile range 1.9-2.2). Compared to pts in the lowest quartile, pts in the highest 
Mg quartile tended to be older men with lower heart rates and blood pressure and higher rates of ischemic HF etiology, creatinine and natriuretic 
peptide levels (all P<0.003) (Table). Over a median follow-up of 9.9 months, every 1 mg/dL increase in Mg was associated with higher ACM (HR=1.8; 
95% CI,1.3-2.3; p<.0001) and CVM+HHF (HR=1.4; 95% CI,1.2-1.8; p=0.002). After adjusting for 23 covariates, Mg was not predictive of ACM 
(p=0.7) or CVM+HHF (p=0.3).
conclusions: Baseline Mg levels vary markedly in the HHFrEF population and are associated with distinct clinical profiles. Despite these 
differences, Mg is not independently associated with worse outcomes. 











Magnesium (mean±SD) 1.7±0.2 2±0 2.1±0 2.5±0.2 <0.001
Demographic Characteristics
Age (mean±SD) 63.4±11.7 64.6±11.9 66.6±11.9 67.7±12.5 <0.001
Male 284 (69.1) 449 (75.5) 424 (76.3) 336 (80) 0.003
Clinical History
EF (mean±SD) 27.3±8.3 28±8 27.9±8.3 26.9±8.2 0.118
QRS duration (mean±SD) 120.6±31.9 122.6±32.4 127.4±35.3 137.3±38.2 <0.001
Atrial Fibrillation/Flutter 133 (32.4) 172 (29) 160 (28.8) 107 (25.5) 0.188
Ischemic Etiology of HF 252 (62.5) 368 (62.4) 370 (67.5) 301 (72.5) 0.003
NYHA class IV 185 (45) 234 (39.3) 184 (33.2) 189 (45.1) <0.001
Coronary Artery Disease 278 (68) 406 (68.4) 397 (71.4) 315 (75) 0.076
Hypertension 296 (72) 432 (72.6) 389 (70) 298 (71) 0.776
Hyperlipidemia 179 (43.8) 267 (45.1) 266 (48) 225 (53.7) 0.017
Diabetes 185 (45) 210 (35.3) 196 (35.3) 153 (36.4) 0.006
Chronic Kidney Disease 76 (18.5) 123 (20.7) 156 (28.1) 183 (43.6) <0.001
Signs, Symptoms and Vital Signs
Dyspnea 360 (88.7) 536 (91.5) 506 (92.3) 376 (91.5) 0.243
JVD 118 (29.4) 138 (23.8) 142 (26.2) 122 (29.8) 0.108
Rales 329 (81) 476 (81.2) 449 (81.8) 343 (83.3) 0.833
Pedal Edema 325 (79.9) 459 (78.3) 442 (80.5) 333 (80.8) 0.746
SBP (mean±SD) 121.5±19.3 122.7±19.6 120.3±19.5 115.6±18.4 <0.001
Heart Rate (mean±SD) 82.5±16.3 80.3±15.8 78±14.6 78.2±15.5 <0.001
Laboratory Parameters
Albumin (mean±SD) 3.6±0.5 3.7±0.5 3.8±0.5 3.8±0.5 <0.001
BNP (median (IQR)) 789 (392-1594) 675 (301-1417) 631 (272-1417) 890 (372-1860) 0.008
BUN (mean±SD) 25.1±11.8 26±11.5 30.7±15.3 41.5±23.1 <0.001
Creatinine (mean±SD) 1.2±0.4 1.3±0.4 1.4±0.7 1.7±0.6 <0.001
Serum sodium (mean±SD) 138.9±4.5 139.8±4.3 140±4.8 139.7±5.4 0.006
Baseline Medications
ACE-inhibitor / ARB 355 (86.6) 505 (85.3) 470 (84.8) 337 (80.2) 0.059
MRA 234 (57.1) 337 (56.9) 292 (52.7) 228 (54.3) 0.419
Beta-Blocker 288 (70.2) 406 (68.6) 398 (71.8) 294 (70) 0.692
Digoxin 227 (55.4) 294 (49.7) 268 (48.4) 179 (42.6) 0.003
Diuretics 401 (97.8) 573 (96.8) 537 (96.9) 410 (97.6) 0.720
Statin 127 (31) 182 (30.7) 196 (35.4) 155 (36.9) 0.100
Clinical Endpoints
All-Cause Mortality 94 (22.9) 146 (24.5) 144 (25.9) 140 (33.3) 0.003
Cardiovascular Mortality and HF Hospitalization 149 (36.3) 230 (38.7) 231 (41.5) 187 (44.5) 0.074
